Oruka’s ORKA-001 psoriasis trial reaches 71.4% PASI 100 response at week 28
AI Summary- Oruka Therapeutics reported week 28 results from its Phase 2a ORKA-001 psoriasis trial.
- PASI 100 responses increased from 63.5% at week 16 to 71.4% at week 28.
- EVERLAST-A will continue through week 52, with comprehensive data planned for December 2026.